Promising drug cocktail aims to wipe out breast cancer before surgery

NCT ID NCT07466303

Not yet recruiting Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial will test a combination of two drugs—serplulimab (an immunotherapy) and SHR-A1811 (a targeted chemotherapy)—given before surgery to women with early-stage triple-negative breast cancer. The main goal is to see how many patients have no cancer left at the time of surgery. About 84 women will take part. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: serplulimab (an immunotherapy drug) and SHR-A1811 (a targeted chemotherapy drug)
What this could lead to: If successful, this combination could become a new pre-surgery treatment option for triple-negative breast cancer, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong: This is a small, early-phase trial with no control group, so results may not be definitive. Side effects from the drug combination are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SERPLULIMAB COMBINED WITH SHR-A1811 AS NEOADJUVANT THERAPY FOR TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

the First Affiliated Hospital of the Air Force Medical University

Xi'an, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.